|
West, Allison H; Blazer, Kathleen R; Stoll, Jessica et al. (2018) Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer 17:495-505
|
|
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
|
|
Veneris, Jennifer Taylor; Darcy, Kathleen M; Mhawech-Fauceglia, Paulette et al. (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146:153-160
|
|
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2017) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer 15:207-212
|
|
Saha, Poornima; Amico, Andrea L; Olopade, Olufunmilayo I (2016) Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer 16:e61-3
|
|
University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 128:1800-1813
|
|
Sweis, Randy F; Spranger, Stefani; Bao, Riyue et al. (2016) Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res 4:563-8
|
|
Curran, Emily; Chen, Xiufen; Corrales, Leticia et al. (2016) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep 15:2357-66
|
|
Sweis, Randy F; Ratain, Mark J (2016) Reply to T.A. Yap et al. J Clin Oncol 34:2432-3
|
|
Pettit, Kristen; Stock, Wendy; Walter, Roland B (2016) Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 57:1527-33
|
Showing the most recent 10 out of 59 publications
